Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma

Alexanian, 1969, Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens, J Am Med Assoc, 208, 1680, 10.1001/jama.1969.03160090040009 Gregory, 1992, Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials, J Clin Oncol, 10, 334, 10.1200/JCO.1992.10.2.334 Barlogie, 1984, Effective treatment of advanced multiple myeloma refractory to alkylating agents, N Engl J Med, 310, 1353, 10.1056/NEJM198405243102104 Samson, 1989, Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma, Lancet, 2, 882, 10.1016/S0140-6736(89)91549-3 Alexanian, 1990, VAD-based regimens as primary treatment for multiple myeloma, Am J Hematol, 33, 86, 10.1002/ajh.2830330203 Segeren, 1999, Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma, Br J Haematol, 105, 127, 10.1111/j.1365-2141.1999.01279.x Gabizon, 1997, Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors, Drugs, 54, 15, 10.2165/00003495-199700544-00005 Hussein, 1998, Phase II study of doxil, vincristine and decadron in newly diagnosed multiple myeloma patients, Blood, 92, 278b Durie, 1975, Salmon S. A clinical staging system for multiple myeloma, Cancer, 36, 842, 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U Jackson, 1981, Pharmacokinetics of vincristine infusion, Cancer Treat Rep, 65, 1043 Drewinko, 1981, The growth fraction of human myeloma cells, Blood, 56, 333, 10.1182/blood.V57.2.333.333 Koskela, 1993, Remesk. VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion, Leuk Lymphoma, 10, 347, 10.3109/10428199309148559 Alexanian, 1983, Prednisone pulse therapy for refractory multiple myeloma, Blood, 62, 572, 10.1182/blood.V62.3.572.572 Monconduit, 1992, VAD or VMBCP in severe multiple myeloma, Br J Haematol, 80, 199, 10.1111/j.1365-2141.1992.tb08901.x Abrahamson, 1996, A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma, Br J Haematol, 94, 659, 10.1046/j.1365-2141.1996.d01-1852.x Anderson, 1995, VAD chemotherapy as remission induction for multiple myeloma, Br J Cancer, 71, 326, 10.1038/bjc.1995.65 Tsiara, 2000, Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data, Eur J Haematol, 65, 118, 10.1034/j.1600-0609.2000.90145.x Hussein, 2002, A phase II trial of pegylated liposomal doxorubicin, vincristine and reduced dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients, Cancer, 95, 2160, 10.1002/cncr.10946